Artificial intelligence is changing how pharmaceutical companies operate, how they develop and study new treatments, and even what form those treatments take.
Pharma companies are now pairing medicines with software — so-called digiceuticals powered by virtual reality and AI. Most of the world’s largest drug companies now have a technology officer in their C-suites. And AI is now being used to help find new drug targets, model diseases, and make clinical trials more efficient.
The expanding use of AI poses new scientific and ethical questions about whether the technology is safe and effective, and whether it could be used, wittingly or unwittingly, to subvert regulatory controls and perpetuate bias in the development of new treatments. STAT national technology correspondent Casey Ross and general assignment reporter Kate Sheridan discuss all this and more.
Download slides here (PDF). You may view the webinar recording below.
